NOD/ShiLtJGpt-Prkdcem26Cd52/Gpt

NOD-Scid|Strain NO.T001492

Knockout (KO)

  • Product Type:
  • Quantity: - +
  • Sex:
  • Age:
  • Genotype:
BASIC INFORMATION
Strain Name: NOD/ShiLtJGpt-Prkdcem26Cd52/Gpt
Strain Number: T001492
Official Symbol: Prkdc
Strain Strategy: T001492.Prkdc Cas9-KO Strategy-EN.pdfT001492.Nod-scid Strain info..pdfT001492.Nod-scid strain info..pdf
Official Full Name: protein kinase, DNA activated, catalytic polypeptide
Also Known As: AI326420,AU019811,DNA-PKcs,DNAPDcs,DNAPK,DNPK1,DOXNPH,HYRC1,XRCC7,dxnph,p460,scid,slip
NCBI Number: 19090
MGI Number: 104779
Chromosome: 16
Deletion (size): -52bp
Research Areas: immunodeficiency,Other immunodeficient strains,Humanization of the immune system,Immunodeficiency
Strain Background: [N000235] NOD/ShiLtJGpt
Modification Type: Knockout (KO)
Inventory Status: Live,Cryopreserved
Sale Status: IF (Available for Distribution)
Health Status: Specific pathogen free (SPF)
Health Report: Please log in to view
Publications: 1. CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK2. Establishment and characterization of a novel ‘double‐hit’follicular lymphoma cell line, FL‐SJC3. TRIM32/USP11 balances ARID1A stability and the oncogenic/tumor-suppressive status of squamous cell carcinoma4. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth5. lncRNA NR2F1‐AS1 promotes breast cancer angiogenesis through activating IGF‐1/IGF‐1R/ERK pathway6. Discovery of 8, 9-seco-ent-Kaurane Diterpenoids as Potential Leads for the Treatment of Triple-Negative Breast Cancer7. Targeting FAPα-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis8. Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells9. miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities10. Alanine-Glyoxylate Aminotransferase Sustains Cancer Stemness Properties through the Upregulation of SOX2 and OCT4 in Hepatocellular Carcinoma Cells11. Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling12. Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer13. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling14. In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy15. PERK reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen16. Characterization of human pluripotent stem cell differentiation by single-cell dual-omics analyses17. Cisplatin-activated ERbeta/DCAF8 positive feedback loop induces chemoresistance in non-small cell lung cancer via PTEN/Akt axis18. Gli1 marks a sentinel muscle stem cell population for muscle regeneration19. Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia20. TSTA3 overexpression promotes malignant characteristics in LUSC by regulating LAMP2-mediated autophagy and tumor microenvironment21. Establishment of a Spontaneous Liver Fibrosis Model in NOD/SCID Mice Induced by Natural Aging22. Predictive Roles of ADAM17 in Patient Survival and Immune Cell Infiltration in Hepatocellular Carcinoma23. VEGFA/NRP-1/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing tumor cell-macrophage crosstalk24. LncRNA LBX2-AS1 inhibits acute myeloid leukemia progression through miR-455-5p/MYLIP axis25. Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer
Gene Family: Armadillo like helical domain containing